Actinium Pharmaceuticals. has been granted a patent for humanized anti-human CD45 antibodies and their pharmaceutical compositions. The patent includes specific claims regarding the variable regions of the immunoglobulin heavy and light chains that define these antibodies. GlobalData’s report on Actinium Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Actinium Pharmaceuticals, Antibody drug conjugates(ADC) cancer therapy was a key innovation area identified from patents. Actinium Pharmaceuticals's grant share as of June 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Humanized anti-human cd45 antibodies and compositions
The granted patent US11981741B2 outlines a series of claims related to anti-huCD45 antibodies and their fragments, which are designed to bind specifically to the huCD45 antigen. The first claim details the structural requirements for these antibodies, specifying particular sequences for the immunoglobulin heavy and light chain variable regions. Notably, it establishes a condition that when the heavy chain variable region includes SEQ ID NO:2, the light chain variable region must not be SEQ ID NO:28. Subsequent claims expand on the antibody compositions, including specific sequences for heavy and light chain immunoglobulin components, as well as complementarity determining regions (CDRs) that define the binding specificity of the antibodies.
Additionally, the patent encompasses various pharmaceutical compositions that incorporate the described antibodies or fragments. This includes radiopharmaceutical compositions that link the antibodies to radionuclides, such as alpha or beta particle emitters, with specific examples including 131I, 225Ac, 177Lu, and 90Y. The claims also cover compositions where the antibodies are chemically conjugated to chelators, such as DOTA or its derivatives, potentially enhancing the therapeutic applications of these antibody constructs in targeted radiotherapy. Overall, the patent presents a comprehensive framework for the development of novel therapeutic agents targeting huCD45, with implications for cancer treatment and other medical applications.
To know more about GlobalData’s detailed insights on Actinium Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
